Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Placebo Controlled, Randomised Evaluation of an Eight Week Primaquine Regimen for the Treatment of Vivax Malaria.
Brief Summary: Plasmodium vivax represents a major health problem throughout the tropics. Outside Africa it accounts for over 50% of cases, affecting an estimated 70-80 million people per year. A substantial proportion of clinical cases are not caused by infective bites of Anopheles spp, but by activation of latent hypnozoites in the liver. These relapses may significantly impede development since each illness may result in 5-15 days of absence from work or school.

Primaquine(PQ) is the only drug available that eliminates hypnozoites, though its use is beset by clinical problems; it may precipitate haemolytic anaemia in individuals deficient in the blood enzyme glucose 6 phosphate dehydrogenase (G6PD). Without affordable G6PD testing, primaquine use is precluded. Evidence suggests, however, that a course of 8 weekly doses may be a safe and effective alternative to the traditional 14 day course of the drug. The aim of the proposed study, therefore, is to test whether 8 weekly doses of primaquine is as effective as the 14 day course at preventing relapse malaria, without the risk of hemolysis in G6PD deficient individuals.


Options:
A: Arm Label: DHA-P 7 days; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin-Piperaquine | Arm Label: DHA-P 14 days; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin-Piperaquine | Arm Label: Chloroquine 7 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Arm Label: Chloroquine 14 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Intervention Type: DRUG; Name: Dihydroartemisinin-Piperaquine; Assigned to Arm(s): DHA-P 7 days | Intervention Type: DRUG; Name: Dihydroartemisinin-Piperaquine; Assigned to Arm(s): DHA-P 14 days | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): Chloroquine 7 days | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): Chloroquine 14 days
B: Arm Label: Cohort 1 Tafenoquine; Type: EXPERIMENTAL; Interventions: Drug: Tafenoquine | Arm Label: Cohort 1-Chloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine + Primaquine | Arm Label: Cohort 2 Tafenoquine; Type: EXPERIMENTAL; Interventions: Drug: tafenoquine | Arm Label: Cohort 2 Chloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine + Primaquine | Intervention Type: DRUG; Name: Tafenoquine; Assigned to Arm(s): Cohort 1 Tafenoquine | Intervention Type: DRUG; Name: Chloroquine + Primaquine; Assigned to Arm(s): Cohort 1-Chloroquine | Intervention Type: DRUG; Name: tafenoquine; Assigned to Arm(s): Cohort 2 Tafenoquine | Intervention Type: DRUG; Name: Chloroquine + Primaquine; Assigned to Arm(s): Cohort 2 Chloroquine
C: Intervention Type: DRUG; Name: primaquine; Assigned to Arm(s): N/A
D: Arm Label: Artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate | Arm Label: Chloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Arm Label: Chloroquine/Primaquine; Type: EXPERIMENTAL; Interventions: Drug: Chloroquine/Primaquine | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): Artesunate | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): Chloroquine | Intervention Type: DRUG; Name: Chloroquine/Primaquine; Assigned to Arm(s): Chloroquine/Primaquine

Answer: C